Who is the manufacturer of ritexitinib? How is the domestic listing situation?

Ritexitinib is a kinase inhibitor targeting severe alopecia areata in adults and adolescents over 12 years old. It is gradually becoming a new treatment option for patients with alopecia areata. Alopecia areata is an autoimmune disease that causes the immune system to mistakenly attack hair follicles, causing inflammation and ultimately hair loss. Ritexitinib effectively reduces inflammatory damage to hair follicles and promotes hair growth by suppressing the activity of the immune system, especially blocking Janus kinase 3 (JAK3) and TEC kinase.

The drug is developed and produced by Pfizer, a world-renowned pharmaceutical company. Its excellent research and development capabilities and strict quality control have made ritexitinib widely recognized around the world. In China, ritexitinib has been approved by the National Medical Products Administration and is available on the domestic market. Patients can purchase it at regular pharmacies according to medical advice to ensure drug safety and quality. However, it is important to note that ritexitinib is not currently covered by medical insurance and is a self-paid drug, and patients need to bear all costs themselves.

Although the price of the originator drug may impose a financial burden on some patients, affordable generic versions have emerged on the international market. For example, the generic drug of ritexitinib produced by Lucius in Laos, with its reliable quality and relatively low price (about a few hundred yuan), provides another viable option for many alopecia areata patients. This progress not only reduces the financial pressure on patients, but also enables more patients to enjoy the therapeutic effects of this innovative drug.

In short, ritexitinib, as a new option for the treatment of alopecia areata, was developed by Pfizer and has been launched in China, bringing new hope to patients. Although the price of original drugs is higher, generic drugs in Laos provide affordable options for patients with limited financial conditions, allowing more people to benefit from this innovative treatment.

References:

https://www.medicalnewstoday.com/articles/drugs-litfulo#side-effects